Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid.
Ascites
HRD
Ovarian cancer
ctDNA
shallowWGS
Journal
Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698
Informations de publication
Date de publication:
06 11 2023
06 11 2023
Historique:
received:
20
04
2023
accepted:
19
09
2023
medline:
8
11
2023
pubmed:
7
11
2023
entrez:
6
11
2023
Statut:
epublish
Résumé
Knowing the homologous recombination deficiency (HRD) status in advanced epithelial ovarian cancer (EOC) is vital for patient management. HRD is determined by BRCA1/BRCA2 pathogenic variants or genomic instability. However, tumor DNA analysis is inconclusive in 15-19% of cases. Peritoneal fluid, available in > 95% of advanced EOC cases, could serve as an alternative source of cell-free tumor DNA (cftDNA) for HRD testing. Limited data show the feasibility of cancer panel gene testing on ascites cfDNA but no study, to date, has investigated HRD testing. We collected ascites/peritoneal washings from 53 EOC patients (19 from retrospective cohort and 34 from prospective cohort) and performed a Cancer Gene Panel (CGP) using NGS for TP53/HR genes and shallow Whole Genome Sequencing (sWGS) for genomic instability on cfDNA. cfDNA was detectable in 49 out of 53 patients (92.5%), including those with limited peritoneal fluid. Median cfDNA was 3700 ng/ml, with a turnaround time of 21 days. TP53 pathogenic variants were detected in 86% (42/49) of patients, all with HGSOC. BRCA1 and BRCA2 pathogenic variants were found in 14% (7/49) and 10% (5/49) of cases, respectively. Peritoneal cftDNA showed high sensitivity (97%), specificity (83%), and concordance (95%) with tumor-based TP53 variant detection. NGS CGP on cftDNA identified BRCA2 pathogenic variants in one case where tumor-based testing failed. sWGS on cftDNA provided informative results even when tumor-based genomic instability testing failed. Profiling cftDNA from peritoneal fluid is feasible, providing a significant amount of tumor DNA. This fast and reliable approach enables HRD testing, including BRCA1/2 mutations and genomic instability assessment. HRD testing on cfDNA from peritoneal fluid should be offered to all primary laparoscopy patients.
Sections du résumé
BACKGROUND
Knowing the homologous recombination deficiency (HRD) status in advanced epithelial ovarian cancer (EOC) is vital for patient management. HRD is determined by BRCA1/BRCA2 pathogenic variants or genomic instability. However, tumor DNA analysis is inconclusive in 15-19% of cases. Peritoneal fluid, available in > 95% of advanced EOC cases, could serve as an alternative source of cell-free tumor DNA (cftDNA) for HRD testing. Limited data show the feasibility of cancer panel gene testing on ascites cfDNA but no study, to date, has investigated HRD testing.
METHODS
We collected ascites/peritoneal washings from 53 EOC patients (19 from retrospective cohort and 34 from prospective cohort) and performed a Cancer Gene Panel (CGP) using NGS for TP53/HR genes and shallow Whole Genome Sequencing (sWGS) for genomic instability on cfDNA.
RESULTS
cfDNA was detectable in 49 out of 53 patients (92.5%), including those with limited peritoneal fluid. Median cfDNA was 3700 ng/ml, with a turnaround time of 21 days. TP53 pathogenic variants were detected in 86% (42/49) of patients, all with HGSOC. BRCA1 and BRCA2 pathogenic variants were found in 14% (7/49) and 10% (5/49) of cases, respectively. Peritoneal cftDNA showed high sensitivity (97%), specificity (83%), and concordance (95%) with tumor-based TP53 variant detection. NGS CGP on cftDNA identified BRCA2 pathogenic variants in one case where tumor-based testing failed. sWGS on cftDNA provided informative results even when tumor-based genomic instability testing failed.
CONCLUSION
Profiling cftDNA from peritoneal fluid is feasible, providing a significant amount of tumor DNA. This fast and reliable approach enables HRD testing, including BRCA1/2 mutations and genomic instability assessment. HRD testing on cfDNA from peritoneal fluid should be offered to all primary laparoscopy patients.
Identifiants
pubmed: 37932736
doi: 10.1186/s12943-023-01864-1
pii: 10.1186/s12943-023-01864-1
pmc: PMC10626673
doi:
Substances chimiques
BRCA1 protein, human
0
BRCA1 Protein
0
BRCA2 protein, human
0
BRCA2 Protein
0
Circulating Tumor DNA
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
178Informations de copyright
© 2023. The Author(s).
Références
Gynecol Oncol. 2021 Sep;162(3):720-727
pubmed: 34454680
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Mol Cancer Ther. 2017 May;16(5):948-955
pubmed: 28468865
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Cancer Biol Ther. 2019;20(1):15-20
pubmed: 30118648
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
Cancer Res Treat. 2020 Jul;52(3):779-788
pubmed: 32106643
Cancer Metastasis Rev. 2016 Sep;35(3):347-76
pubmed: 27392603
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Nat Rev Clin Oncol. 2022 Sep;19(9):600-612
pubmed: 35915225
N Engl J Med. 2019 Dec 19;381(25):2403-2415
pubmed: 31562800
Ann Oncol. 2022 Aug;33(8):750-768
pubmed: 35809752
Lancet. 2019 Mar 23;393(10177):1240-1253
pubmed: 30910306
J Clin Oncol. 2022 Dec 1;40(34):3952-3964
pubmed: 35658487
Ann Oncol. 2023 Apr;34(4):389-396
pubmed: 36709039
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Bioinformatics. 2020 Jun 1;36(12):3888-3889
pubmed: 32315385